Kathleen N. Moore, MD, MS, University of Oklahoma

Future of Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Novel Targets for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Endometrial Cancer: Chemo-Free Regimens on the Horizon

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Emerging Agents: Treatment of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Sequencing for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Recurrent Endometrial Cancer: Safety of Combination Therapy

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Combination Therapy for Recurrent Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Emerging ICI Therapy for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Immune Checkpoint Inhibitors in Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG-258 and PORTEC-3 Studies in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG-249 Study in Early-Stage Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG 0209 Study in Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Role of Biomarker Testing in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Risk Classification of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Overview of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Systemic Management of Ovarian Cancer: Closing Thoughts

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Novel Combination Strategies in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Recurrent Ovarian Cancer: Novel Agents Under Investigation

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Bevacizumab’s Role in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

PARP Inhibition’s Role in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Frontline Ovarian Cancer Management: Ongoing Clinical Trials

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Considerations for the JAVELIN OVARIAN 100 Study

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Ovarian Cancer: Maintenance Following Frontline Bevacizumab

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Ovarian Cancer: Updates to NCCN Guidelines

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Treating Ovarian Cancer Based on HRD Status

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Ovarian Cancer: What is the Role of HRD Testing?

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Ovarian Cancer: Factors in Deciding on Maintenance Therapy

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Practical Applications of PRIMA in Ovarian Cancer Management

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Articles by Kathleen N. Moore, MD, MS, University of Oklahoma

Future of Advanced Endometrial Cancer

Novel Targets for Advanced Endometrial Cancer

Endometrial Cancer: Chemo-Free Regimens on the Horizon

Emerging Agents: Treatment of Endometrial Cancer

Sequencing for Advanced Endometrial Cancer

Recurrent Endometrial Cancer: Safety of Combination Therapy

Combination Therapy for Recurrent Endometrial Cancer

Emerging ICI Therapy for Advanced Endometrial Cancer

Immune Checkpoint Inhibitors in Advanced Endometrial Cancer

GOG-258 and PORTEC-3 Studies in Endometrial Cancer

GOG-249 Study in Early-Stage Endometrial Cancer

GOG 0209 Study in Advanced Endometrial Cancer

Role of Biomarker Testing in Endometrial Cancer

Risk Classification of Endometrial Cancer

Overview of Endometrial Cancer

Systemic Management of Ovarian Cancer: Closing Thoughts

Novel Combination Strategies in Recurrent Ovarian Cancer

Recurrent Ovarian Cancer: Novel Agents Under Investigation

Bevacizumab’s Role in Recurrent Ovarian Cancer

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

PARP Inhibition’s Role in Recurrent Ovarian Cancer

Frontline Ovarian Cancer Management: Ongoing Clinical Trials

Considerations for the JAVELIN OVARIAN 100 Study

Ovarian Cancer: Maintenance Following Frontline Bevacizumab

Ovarian Cancer: Updates to NCCN Guidelines

Treating Ovarian Cancer Based on HRD Status

Ovarian Cancer: What is the Role of HRD Testing?

Ovarian Cancer: Factors in Deciding on Maintenance Therapy

PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer

Practical Applications of PRIMA in Ovarian Cancer Management

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma